Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 3 × First Line Metastatic Breast Cancer × exemestane × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Breast Neoplasms 59 Neoplasm Metastasis 3 Breast Neoplasms, Male 3 Neoplasms 2 Sleep Wake Disorders 1 Ovarian Neoplasms 1 First Line Metastatic Breast Cancer 1 Fatigue 1 Carcinoma, Intraductal, Noninfiltrating 1 Bulbo-Spinal Atrophy, X-Linked 1 Breast Carcinoma In Situ 1 Breast Cancer Metastatic 1 Breast Cancer Female 1 Advanced Breast Cancer 1

Interventions

exemestane 1 Paclitaxel 1 Bevacizumab 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT01303679 2023-09-06

1st Line Treatment of Bevacizumab-Taxane vs Bevacizumab-Exemestane in Metastatic Breast Cancer

ARCAGY/ GINECO GROUP

Phase 3 Terminated

First Line Metastatic Breast Cancer

Data powered by HemOnc (CC BY 4.0) Colophon ⚡